Shanghai BDgene Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2018)

Organization Overview

First Clinical Trial
2020
NCT04560790
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Shanghai BDgene Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

bd111 (1 trial)

Drugs in Phase 1 Trials (1)

bd311 (1 trial)

Drugs in Other Trials (1)

bd211 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blindness (Phase 2)

Herpes Simplex (Phase 2)

Keratitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3